Amicus Therapeutics Offering out of the Box Solutions

We all hate diseases. Be it the simple flu or diarrhea; the outcome is the same. Due to the discomfort often associated with illness, no one in the world wishes to be sick, so I tend to think. Since the advent of the human race, diseases have become a part of life. Although society readily welcomes most illnesses, there are others that have always been taboo, diseases like leprosy.


However, you may at times find a small category of people suffering from rare and orphan diseases, illnesses that get often overlooked (,-NJ-jobs.html). For centuries, such individuals have endured a lot of pain in the hand of untreatable ailments due to a shortage of medical infrastructure.


Despite the prevailing circumstances, Amicus Therapeutics has come of age to offer people suffering from rare diseases with hope and future. At Amicus Therapeutics, patients get a full range of products and services. The most prominent rare diseases include Epidermolysis Bullosa, Lysosomal Storage Disorders Fabry, and Pompe Disease.


Fifteen years after its inception, Amicus Therapeutics still strives to find cures for the ailments mentioned above. By investing heavily in medical research, Amicus Therapeutics has helped achieve SD-01 and Migalastat (YahooFinance). By working closely with manufacturers, the drugs are now available for mass consumption. Amicus Therapeutics first setup base in New Jersey but has since expanded its operations to San Diego.


For Amicus Therapeutics to provide patients with quality products and services, the institution has had no other choice but to hire close to five hundred employees. Thanks to its unique management outfit, Amicus Therapeutics has once again given hope to a ‘community’ that was once hopeless. Over the years, Amicus Therapeutics has been on the receiving end to some rare signs of good will. It is organizations like The Michael J. Fox Foundation and the Alzheimer’s Drug Discovery Foundation that have generously contributed funds to see to it that Amicus Therapeutics continues with its excellent work. Although there is a lot of pending work for Amicus Therapeutics in as far as rare and orphan diseases are concerned, the organization seems to be on the right path.

More about Amicus Therapeutics on Twitter